List of Tables
Table 1. Global Short-acting Interferon Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Short-acting Interferon Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Short-acting Interferon Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Short-acting Interferon Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Short-acting Interferon Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Short-acting Interferon Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Short-acting Interferon Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Short-acting Interferon Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Short-acting Interferon Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Short-acting Interferon Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Short-acting Interferon Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Short-acting Interferon Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting Interferon Injection as of 2024)
Table 16. Global Short-acting Interferon Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Short-acting Interferon Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Short-acting Interferon Injection Manufacturing Base and Headquarters
Table 19. Global Short-acting Interferon Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Short-acting Interferon Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Short-acting Interferon Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Short-acting Interferon Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Short-acting Interferon Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Short-acting Interferon Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Short-acting Interferon Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Short-acting Interferon Injection Sales by Application (2026-2031) & (K Units)
Table 30. Short-acting Interferon Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Short-acting Interferon Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Short-acting Interferon Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Short-acting Interferon Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Short-acting Interferon Injection Growth Accelerators and Market Barriers
Table 37. North America Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Short-acting Interferon Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Short-acting Interferon Injection Growth Accelerators and Market Barriers
Table 40. Europe Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Short-acting Interferon Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Short-acting Interferon Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Short-acting Interferon Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Short-acting Interferon Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Short-acting Interferon Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Short-acting Interferon Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Bayer Corporation Information
Table 51. Bayer Description and Major Businesses
Table 52. Bayer Product Models, Descriptions and Specifications
Table 53. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Bayer Sales Value Proportion by Product in 2024
Table 55. Bayer Sales Value Proportion by Application in 2024
Table 56. Bayer Sales Value Proportion by Geographic Area in 2024
Table 57. Bayer Short-acting Interferon Injection SWOT Analysis
Table 58. Bayer Recent Developments
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Major Businesses
Table 61. Novartis Product Models, Descriptions and Specifications
Table 62. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Novartis Sales Value Proportion by Product in 2024
Table 64. Novartis Sales Value Proportion by Application in 2024
Table 65. Novartis Sales Value Proportion by Geographic Area in 2024
Table 66. Novartis Short-acting Interferon Injection SWOT Analysis
Table 67. Novartis Recent Developments
Table 68. Biogen Corporation Information
Table 69. Biogen Description and Major Businesses
Table 70. Biogen Product Models, Descriptions and Specifications
Table 71. Biogen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Biogen Sales Value Proportion by Product in 2024
Table 73. Biogen Sales Value Proportion by Application in 2024
Table 74. Biogen Sales Value Proportion by Geographic Area in 2024
Table 75. Biogen Short-acting Interferon Injection SWOT Analysis
Table 76. Biogen Recent Developments
Table 77. Merck KGaA Corporation Information
Table 78. Merck KGaA Description and Major Businesses
Table 79. Merck KGaA Product Models, Descriptions and Specifications
Table 80. Merck KGaA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Merck KGaA Sales Value Proportion by Product in 2024
Table 82. Merck KGaA Sales Value Proportion by Application in 2024
Table 83. Merck KGaA Sales Value Proportion by Geographic Area in 2024
Table 84. Merck KGaA Short-acting Interferon Injection SWOT Analysis
Table 85. Merck KGaA Recent Developments
Table 86. Anhui Anke Biotechnology Corporation Information
Table 87. Anhui Anke Biotechnology Description and Major Businesses
Table 88. Anhui Anke Biotechnology Product Models, Descriptions and Specifications
Table 89. Anhui Anke Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Anhui Anke Biotechnology Sales Value Proportion by Product in 2024
Table 91. Anhui Anke Biotechnology Sales Value Proportion by Application in 2024
Table 92. Anhui Anke Biotechnology Sales Value Proportion by Geographic Area in 2024
Table 93. Anhui Anke Biotechnology Short-acting Interferon Injection SWOT Analysis
Table 94. Anhui Anke Biotechnology Recent Developments
Table 95. Beijing Tri-Prime Gene Pharmaceutical Corporation Information
Table 96. Beijing Tri-Prime Gene Pharmaceutical Description and Major Businesses
Table 97. Beijing Tri-Prime Gene Pharmaceutical Product Models, Descriptions and Specifications
Table 98. Beijing Tri-Prime Gene Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Beijing Tri-Prime Gene Pharmaceutical Recent Developments
Table 100. Beijing Kawin Technology Corporation Information
Table 101. Beijing Kawin Technology Description and Major Businesses
Table 102. Beijing Kawin Technology Product Models, Descriptions and Specifications
Table 103. Beijing Kawin Technology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Beijing Kawin Technology Recent Developments
Table 105. Shan Dong Kexing Biopharm Corporation Information
Table 106. Shan Dong Kexing Biopharm Description and Major Businesses
Table 107. Shan Dong Kexing Biopharm Product Models, Descriptions and Specifications
Table 108. Shan Dong Kexing Biopharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Shan Dong Kexing Biopharm Recent Developments
Table 110. Shanghai Huaxin High Biotechnology Corporation Information
Table 111. Shanghai Huaxin High Biotechnology Description and Major Businesses
Table 112. Shanghai Huaxin High Biotechnology Product Models, Descriptions and Specifications
Table 113. Shanghai Huaxin High Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Shanghai Huaxin High Biotechnology Recent Developments
Table 115. Harbin Pharmaceutical Group Corporation Information
Table 116. Harbin Pharmaceutical Group Description and Major Businesses
Table 117. Harbin Pharmaceutical Group Product Models, Descriptions and Specifications
Table 118. Harbin Pharmaceutical Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Harbin Pharmaceutical Group Recent Developments
Table 120. Sinobioway Biomedicine Corporation Information
Table 121. Sinobioway Biomedicine Description and Major Businesses
Table 122. Sinobioway Biomedicine Product Models, Descriptions and Specifications
Table 123. Sinobioway Biomedicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Sinobioway Biomedicine Recent Developments
Table 125. 3SBio Group Corporation Information
Table 126. 3SBio Group Description and Major Businesses
Table 127. 3SBio Group Product Models, Descriptions and Specifications
Table 128. 3SBio Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. 3SBio Group Recent Developments
Table 130. Changchun Heber Biological Technology Corporation Information
Table 131. Changchun Heber Biological Technology Description and Major Businesses
Table 132. Changchun Heber Biological Technology Product Models, Descriptions and Specifications
Table 133. Changchun Heber Biological Technology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Changchun Heber Biological Technology Recent Developments
Table 135. Key Raw Materials Distribution
Table 136. Raw Materials Key Suppliers
Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 138. Milestones in Production Technology Evolution
Table 139. Distributors List
Table 140. Market Trends and Market Evolution
Table 141. Market Drivers and Opportunities
Table 142. Market Challenges, Risks, and Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Short-acting Interferon Injection Product Picture
Figure 2. Global Short-acting Interferon Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Interferon α1b Injection Product Picture
Figure 4. Interferon α2a Injection Product Picture
Figure 5. Interferon α2b Injection Product Picture
Figure 6. Interferon β1a Injection Product Picture
Figure 7. Interferon β1b Injection Product Picture
Figure 8. Global Short-acting Interferon Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Viral Diseases
Figure 10. Malignant Tumors
Figure 11. Short-acting Interferon Injection Report Years Considered
Figure 12. Global Short-acting Interferon Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 14. Global Short-acting Interferon Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Short-acting Interferon Injection Revenue Market Share by Region (2020-2031)
Figure 16. Global Short-acting Interferon Injection Sales (2020-2031) & (K Units)
Figure 17. Global Short-acting Interferon Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Short-acting Interferon Injection Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Short-acting Interferon Injection Sales Volume Market Share in 2024
Figure 20. Global Short-acting Interferon Injection Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Interferon α1b Injection Revenue Market Share by Manufacturer in 2024
Figure 23. Interferon α2a Injection Revenue Market Share by Manufacturer in 2024
Figure 24. Interferon α2b Injection Revenue Market Share by Manufacturer in 2024
Figure 25. Interferon β1a Injection Revenue Market Share by Manufacturer in 2024
Figure 26. Interferon β1b Injection Revenue Market Share by Manufacturer in 2024
Figure 27. Global Short-acting Interferon Injection Sales Market Share by Type (2020-2031)
Figure 28. Global Short-acting Interferon Injection Revenue Market Share by Type (2020-2031)
Figure 29. Global Short-acting Interferon Injection Sales Market Share by Application (2020-2031)
Figure 30. Global Short-acting Interferon Injection Revenue Market Share by Application (2020-2031)
Figure 31. North America Short-acting Interferon Injection Sales YoY (2020-2031) & (K Units)
Figure 32. North America Short-acting Interferon Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers Short-acting Interferon Injection Sales Revenue (US$ Million) in 2024
Figure 34. North America Short-acting Interferon Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America Short-acting Interferon Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America Short-acting Interferon Injection Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America Short-acting Interferon Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 39. Canada Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 41. Europe Short-acting Interferon Injection Sales YoY (2020-2031) & (K Units)
Figure 42. Europe Short-acting Interferon Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers Short-acting Interferon Injection Sales Revenue (US$ Million) in 2024
Figure 44. Europe Short-acting Interferon Injection Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe Short-acting Interferon Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe Short-acting Interferon Injection Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe Short-acting Interferon Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 49. France Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 51. Italy Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 52. Russia Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Short-acting Interferon Injection Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific Short-acting Interferon Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers Short-acting Interferon Injection Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific Short-acting Interferon Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific Short-acting Interferon Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific Short-acting Interferon Injection Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific Short-acting Interferon Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 61. Japan Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 64. India Short-acting Interferon Injection Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America Short-acting Interferon Injection Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America Short-acting Interferon Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers Short-acting Interferon Injection Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America Short-acting Interferon Injection Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America Short-acting Interferon Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America Short-acting Interferon Injection Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America Short-acting Interferon Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa Short-acting Interferon Injection Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa Short-acting Interferon Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers Short-acting Interferon Injection Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa Short-acting Interferon Injection Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America Short-acting Interferon Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa Short-acting Interferon Injection Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa Short-acting Interferon Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa Short-acting Interferon Injection Revenue (2020-2025) & (US$ Million)
Figure 85. Short-acting Interferon Injection Industry Chain Mapping
Figure 86. Regional Short-acting Interferon Injection Manufacturing Base Distribution (%)
Figure 87. Global Short-acting Interferon Injection Production Market Share by Region (2020-2031)
Figure 88. Short-acting Interferon Injection Production Process
Figure 89. Regional Short-acting Interferon Injection Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
